Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Omnicom Group Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.77 (market cap $29.60B), while Omnicom Group Inc. trades at $85.22 (market cap $23.58B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OMC | |
|---|---|---|
Market Cap | $29.60B | $23.58B |
Sector | Health | Media |
52-Week High | $491.22 | $86.22 |
52-Week Low | $205.48 | $67.27 |
Enterprise Value | $27.56B | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Omnicom Group (OMC) trades at $85.34, up 0.82% today, with a bullish technical signal from moving averages and a consensus price target of $107.00. Recent Q2 2026 earnings beat expectations with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company shows strong cash flow from operations at $2.94 billion in 2025 and pays a $0.80 quarterly dividend.
Outlook is positive with post-merger synergies driving margin expansion, but high P/E of 232.3 and integration risks from the Interpublic acquisition pose challenges. Analyst sentiment is mixed with 32% buy ratings, highlighting value potential amid execution concerns. Key catalysts include sustained organic growth and cost savings realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
